Table 2
Open in new tab

Comparative outcomes in patients with HF and type 2 diabetes initiating SGLT2i vs. sitagliptin under 365-day intention-to-treat follow-up

Exposure groupUnweightedPS-weighted
SGLT2iSitagliptinSGLT2iSitagliptin
Sample size16 25343 35216 17242 962
Primary composite endpoint of all-cause mortality or worsening HF
 Total events1672978716676204
 Follow-up, person-years11 81533 90311 78031 314
 Incidence rate (95% CI)/100 person-years14.2 (13.5–14.8)28.9 (28.3–29.4)14.2 (13.5–14.8)19.8 (19.3–20.3)
 HR (95% CI)0.49 (0.46–0.51)Ref0.72 (0.67–0.77)Ref
Single components of the primary composite endpoint
All-cause mortality
 Total events63747696362468
 Follow-up, person-years12 31637 01812 28033 384
 Incidence rate (95% CI)/100 person-years5.2 (4.8–5.6)12.9 (12.5–13.3)5.2 (4.8–5.6)7.4 (7.1–7.7)
 HR (95% CI)0.40 (0.37–0.44)Ref0.70 (0.63–0.78)Ref
Hospitalization for heart failure
 Total events75549897523147
 Follow-up, person-years12 01534 76911 98032 014
 Incidence rate (95% CI)/100 person-years6.3 (5.8–6.7)14.3 (14.0–14.8)6.3 (5.8–6.7)9.8 (9.5–10.2)
 HR (95% CI)0.43 (0.40–0.47)Ref0.64 (0.58–0.70)Ref
Urgent visit requiring intravenous diuretics
 Total events58426455832041
 Follow-up, person-years12 06835 77412 03332 431
 Incidence rate (95% CI)/100 person-years4.8 (4.5–5.2)7.4 (7.1–7.7)4.8 (4.5–5.3)6.3 (6.0–6.6)
 HR (95% CI)0.65 (0.59–0.71)Ref0.77 (0.69–0.86)Ref
Exposure groupUnweightedPS-weighted
SGLT2iSitagliptinSGLT2iSitagliptin
Sample size16 25343 35216 17242 962
Primary composite endpoint of all-cause mortality or worsening HF
 Total events1672978716676204
 Follow-up, person-years11 81533 90311 78031 314
 Incidence rate (95% CI)/100 person-years14.2 (13.5–14.8)28.9 (28.3–29.4)14.2 (13.5–14.8)19.8 (19.3–20.3)
 HR (95% CI)0.49 (0.46–0.51)Ref0.72 (0.67–0.77)Ref
Single components of the primary composite endpoint
All-cause mortality
 Total events63747696362468
 Follow-up, person-years12 31637 01812 28033 384
 Incidence rate (95% CI)/100 person-years5.2 (4.8–5.6)12.9 (12.5–13.3)5.2 (4.8–5.6)7.4 (7.1–7.7)
 HR (95% CI)0.40 (0.37–0.44)Ref0.70 (0.63–0.78)Ref
Hospitalization for heart failure
 Total events75549897523147
 Follow-up, person-years12 01534 76911 98032 014
 Incidence rate (95% CI)/100 person-years6.3 (5.8–6.7)14.3 (14.0–14.8)6.3 (5.8–6.7)9.8 (9.5–10.2)
 HR (95% CI)0.43 (0.40–0.47)Ref0.64 (0.58–0.70)Ref
Urgent visit requiring intravenous diuretics
 Total events58426455832041
 Follow-up, person-years12 06835 77412 03332 431
 Incidence rate (95% CI)/100 person-years4.8 (4.5–5.2)7.4 (7.1–7.7)4.8 (4.5–5.3)6.3 (6.0–6.6)
 HR (95% CI)0.65 (0.59–0.71)Ref0.77 (0.69–0.86)Ref

CI, confidence interval; HF, heart failure; HR, hazard ratio; PS, propensity score; SGLT2i, sodium–glucose cotransporter 2 inhibitors. Hazard ratios are shown in bold.

Table 2
Open in new tab

Comparative outcomes in patients with HF and type 2 diabetes initiating SGLT2i vs. sitagliptin under 365-day intention-to-treat follow-up

Exposure groupUnweightedPS-weighted
SGLT2iSitagliptinSGLT2iSitagliptin
Sample size16 25343 35216 17242 962
Primary composite endpoint of all-cause mortality or worsening HF
 Total events1672978716676204
 Follow-up, person-years11 81533 90311 78031 314
 Incidence rate (95% CI)/100 person-years14.2 (13.5–14.8)28.9 (28.3–29.4)14.2 (13.5–14.8)19.8 (19.3–20.3)
 HR (95% CI)0.49 (0.46–0.51)Ref0.72 (0.67–0.77)Ref
Single components of the primary composite endpoint
All-cause mortality
 Total events63747696362468
 Follow-up, person-years12 31637 01812 28033 384
 Incidence rate (95% CI)/100 person-years5.2 (4.8–5.6)12.9 (12.5–13.3)5.2 (4.8–5.6)7.4 (7.1–7.7)
 HR (95% CI)0.40 (0.37–0.44)Ref0.70 (0.63–0.78)Ref
Hospitalization for heart failure
 Total events75549897523147
 Follow-up, person-years12 01534 76911 98032 014
 Incidence rate (95% CI)/100 person-years6.3 (5.8–6.7)14.3 (14.0–14.8)6.3 (5.8–6.7)9.8 (9.5–10.2)
 HR (95% CI)0.43 (0.40–0.47)Ref0.64 (0.58–0.70)Ref
Urgent visit requiring intravenous diuretics
 Total events58426455832041
 Follow-up, person-years12 06835 77412 03332 431
 Incidence rate (95% CI)/100 person-years4.8 (4.5–5.2)7.4 (7.1–7.7)4.8 (4.5–5.3)6.3 (6.0–6.6)
 HR (95% CI)0.65 (0.59–0.71)Ref0.77 (0.69–0.86)Ref
Exposure groupUnweightedPS-weighted
SGLT2iSitagliptinSGLT2iSitagliptin
Sample size16 25343 35216 17242 962
Primary composite endpoint of all-cause mortality or worsening HF
 Total events1672978716676204
 Follow-up, person-years11 81533 90311 78031 314
 Incidence rate (95% CI)/100 person-years14.2 (13.5–14.8)28.9 (28.3–29.4)14.2 (13.5–14.8)19.8 (19.3–20.3)
 HR (95% CI)0.49 (0.46–0.51)Ref0.72 (0.67–0.77)Ref
Single components of the primary composite endpoint
All-cause mortality
 Total events63747696362468
 Follow-up, person-years12 31637 01812 28033 384
 Incidence rate (95% CI)/100 person-years5.2 (4.8–5.6)12.9 (12.5–13.3)5.2 (4.8–5.6)7.4 (7.1–7.7)
 HR (95% CI)0.40 (0.37–0.44)Ref0.70 (0.63–0.78)Ref
Hospitalization for heart failure
 Total events75549897523147
 Follow-up, person-years12 01534 76911 98032 014
 Incidence rate (95% CI)/100 person-years6.3 (5.8–6.7)14.3 (14.0–14.8)6.3 (5.8–6.7)9.8 (9.5–10.2)
 HR (95% CI)0.43 (0.40–0.47)Ref0.64 (0.58–0.70)Ref
Urgent visit requiring intravenous diuretics
 Total events58426455832041
 Follow-up, person-years12 06835 77412 03332 431
 Incidence rate (95% CI)/100 person-years4.8 (4.5–5.2)7.4 (7.1–7.7)4.8 (4.5–5.3)6.3 (6.0–6.6)
 HR (95% CI)0.65 (0.59–0.71)Ref0.77 (0.69–0.86)Ref

CI, confidence interval; HF, heart failure; HR, hazard ratio; PS, propensity score; SGLT2i, sodium–glucose cotransporter 2 inhibitors. Hazard ratios are shown in bold.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close